IRONWOOD PHARMACEUTICALS, INC. Paid-in-Kind Interest
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Paid-in-Kind Interest of $808.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:PaidInKindInterest · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2026-06-30 was $389.00K, a 6.49% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2026-03-31 was $419.00K, a 0.72% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2025-12-31 was $418.00K, a 0.72% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. paid-in-kind interest for the quarter ending 2025-09-30 was $418.00K, a 19.43% increase year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. paid-in-kind interest for fiscal 2025 was $1.67M, a 12.39% decline from fiscal 2024.
- IRONWOOD PHARMACEUTICALS, INC. paid-in-kind interest for fiscal 2024 was $1.90M.
| Period end | Paid-in-Kind Interest 3 month | Paid-in-Kind Interest 6 month | Paid-in-Kind Interest 9 month | Paid-in-Kind Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $389.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $808.00K 10-Q · filed 2026-08-06 | $1.23M derived: sum of 3 quarters · filed 2026-08-06 | $1.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $419.00K 10-Q · filed 2026-05-07 | $837.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.25M derived: sum of 3 quarters · filed 2026-05-07 | $1.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $418.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $836.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.25M derived: sum of 3 quarters · filed 2026-08-06 | $1.67M 10-K · filed 2026-02-26 |
| 2025-09-30 | $418.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $834.00K derived: sum of 2 quarters · filed 2026-08-06 | $1.25M 10-Q · filed 2025-11-10 | $1.67M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $416.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $832.00K 10-Q · filed 2026-08-06 | $1.25M derived: sum of 3 quarters · filed 2026-08-06 | $1.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $416.00K 10-Q · filed 2026-05-07 | $831.00K derived: sum of 2 quarters · filed 2026-05-07 | $1.18M derived: sum of 3 quarters · filed 2026-05-07 | $1.73M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $415.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $765.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.31M derived: sum of 3 quarters · filed 2026-02-26 | $1.90M 10-K · filed 2026-02-26 |
| 2024-09-30 | $350.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $900.00K derived: sum of 2 quarters · filed 2025-11-10 | $1.49M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | $550.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $1.14M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | $589.00K 10-Q · filed 2025-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |